Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1634 1656 1677 1681 1682 1683 1699 1798 4100 4144
This examiner grants 42% of resolved cases
Robert Thomas Crow works in Tech Center 4100 and Art Unit 1634, where he has 722 resolved cases. The examiner has an allowance rate of 41.7 percent. The median days to allowance is 1452, which represents the timeframe for applications that reach a grant under his supervision.
The interview lift is 32.7 percent. This 32.7 percent lift is a significant factor, suggesting that an interview can substantially improve the 41.7 percent allowance rate. The 1452 median days to allowance is based on a large sample of 722 cases, providing a reliable expectation for the duration of prosecution.
Practitioners should prioritize interviews given the 32.7 percent lift. While the 41.7 percent allowance rate and 1452 median days to allowance indicate a challenging environment, the examiner appears responsive to oral advocacy. The 722 resolved cases provide a stable basis for planning strategy in Tech Center 4100.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18889917 | METHOD FOR NANOPORE RNA CHARACTERISATION | Non-Final OA | Oxford Nanopore Technologies PLC |
| 18010826 | METHOD | Non-Final OA | Oxford Nanopore Technologies PLC |
| 18160816 | METHOD | Non-Final OA | Oxford Nanopore Technologies PLC |
| 18585357 | FLUID DELIVERY METHODS | Non-Final OA | 10x Genomics, Inc. |
| 18542038 | METHODS AND COMPOSITIONS FOR ASSESSING PERFORMANCE | Non-Final OA | 10x Genomics, Inc. |
| 17909844 | Heteromultivalent Spherical Nucleic Acids and Uses in Therapeutic and Diagnostic Applications | Non-Final OA | Emory University |
| 17929809 | METHODS AND SYSTEMS FOR PROCESSING TIME-RESOLVED SIGNAL INTENSITY DATA | Final Rejection | The Regents of The University of Michigan |
| 17783750 | COMPOSITIONS AND METHODS FOR LIGHT-DIRECTED BIOMOLECULAR BARCODING | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18050688 | METHODS AND COMPOSITIONS USEFUL FOR NUCLEIC ACID SEQUENCING | Non-Final OA | Singular Genomics Systems, Inc. |
| 18027978 | SAMPLE PROCESSING DEVICE, SAMPLE PROCESSING APPARATUS, AND SAMPLE PROCESSING METHOD | Final Rejection | Hitachi High-Tech Corporation |
| 18423678 | HYBRIDIZATION COMPOSITIONS AND METHODS USING FORMAMIDE | Non-Final OA | Agilent Technologies, Inc. |
| 18453947 | HYBRIDIZATION COMPOSITIONS AND METHODS | Final Rejection | Agilent Technologies, Inc. |
| 19264527 | SPATIALLY ENCODED BIOLOGICAL ASSAYS | Final Rejection | Prognosys Biosciences, Inc. |
| 19264491 | SPATIALLY ENCODED BIOLOGICAL ASSAYS | Final Rejection | Prognosys Biosciences, Inc. |
| 18021248 | LIQUID CRYSTAL BIOSENSOR WITH ULTRAHIGH SENSITIVITY AND SELECTIVITY | Final Rejection | Purdue Research Foundation |
| 19192017 | DETECTION AND DIGITAL QUANTITATION OF MULTIPLE TARGETS | Final Rejection | Countable Labs, Inc. |
| 16713657 | COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5 HYDROXYMETHYLCYTOSINE (5-hmC) | Non-Final OA | THE UNIVERSITY OF CHICAGO |
| 18420048 | CONCENTRATING A TARGET MOLECULE FOR SENSING BY A NANOPORE | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 18348235 | TRANSLOCATION CONTROL FOR SENSING BY A NANOPORE | Final Rejection | Roche Sequencing Solutions, Inc. |
| 17769536 | METHODS FOR MULTI-FOCAL IMAGING FOR MOLECULAR PROFILING | Non-Final OA | Children's Medical Center Corporation |
| 18618263 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING | Non-Final OA | Illumina, Inc. |
| 18389877 | MULTI-SURFACE BIOLOGICAL SAMPLE IMAGING SYSTEM AND METHOD | Non-Final OA | ILLUMINA, INC. |
| 18467770 | NANOPARTICLE WITH POLYNUCLEOTIDE BINDING SITE AND METHOD OF MAKING THEREOF | Final Rejection | ILLUMINA, INC |
| 18343696 | SEQUENCING NANOPARTICLES AND METHODS OF MAKING THE SAME | Final Rejection | ILLUMINA, INC. |
| 18176761 | FUNCTIONALIZED NANOSTRUCTURES AND FLOW CELL DEPRESSIONS | Final Rejection | ILLUMINA, INC. |
| 18164341 | Microfluidic Droplet Generators | Non-Final OA | ILLUMINA, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy